小体型成人植入HeartMate 3左心室辅助装置后的结局
基于MOMENTUM 3关键试验及其持续准入方案队列,将1015例HeartMate 3患者按体表面积分为≤1.70 m²组(小体型,n=82)和>1.70 m²组(大体型,n=933),比较2年复合终点及不良事件。两组2年复合终点达标比例均为77%(校正风险比1.14,95%CI 0.68-1.91,P=.62),小体型与大体型患者结局相当。
要点
- 小体型组(BSA≤1.70 m²)2年复合终点达标比例77%,大体型组(BSA>1.70 m²)亦为77%,校正HR 1.14(95%CI 0.68-1.91,P=.62)。
- 脓毒症(6.1% vs 14.9%,P=.029)和心律失常(24.4% vs 35.3%,P=.005)在大体型组更高。
- 小体型不应作为拒绝HeartMate 3植入的理由(适用于其他方面适合持久机械循环支持的患者)。
核心结论
- 小体型与大体型患者植入HeartMate 3后的结局相当。
- 小体型不应被用来拒绝给其他方面适合持久机械循环支持的患者植入HeartMate 3。
研究设计与样本
- 基于MOMENTUM 3关键试验及其持续准入方案队列的分析,共纳入1015例HeartMate 3患者。
- 按体表面积分为小体型组(BSA≤1.70 m²,n=82)和大体型组(BSA>1.70 m²,n=933)。
- 复合主要终点为2年无致残性卒中或无需因装置故障而再次手术更换或移除装置的生存。
主要发现
- 小体型组女性比例更高(56.1% vs 17.7%,P<.001),糖尿病(28.1% vs 43.9%,P=.005)和高血压(51.2% vs 71.9%,P<.001)患病率更低。
- 小体型组中位标化左心室舒张末内径更大(40 vs 33 mm/m²,P<.001),中位血清肌酐更低(1.1 vs 1.3 mg/dL,P<.001)。
- 两组2年复合终点达标比例均为77%(校正风险比1.14,95%CI 0.68-1.91,P=.62)。
- 除脓毒症(6.1% vs 14.9%,P=.029)和心律失常(24.4% vs 35.3%,P=.005)在大体型组更高外,两组2年不良事件发生率相似。
临床怎么用
- 作者认为,小体型不应被用来拒绝给其他方面适合持久机械循环支持的患者植入HeartMate 3。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Outcomes in patients with smaller body size after HeartMate 3 left ventricular assist device (HM3) implantation are not well characterized. We sought to evaluate outcomes in smaller vs larger body surface area (BSA) patients in the MOMENTUM 3 pivotal trial and its Continued Access Protocol cohort. METHODS: The analysis cohort included 1015 HM3 patients divided into 2 groups: BSA ≤1.70 m2 (small patients, n = 82) and BSA >1.70 m2 (large patients, n = 933). The composite primary end point was survival at 2 years free of disabling stroke or reoperation to replace or to remove a malfunctioning device. Adverse events were compared between groups. RESULTS: Smaller patients were more frequently women (56.1% vs 17.7%; P < .001) and had lower prevalence of diabetes (28.1% vs 43.9%; P = .005) and hypertension (51.2% vs 71.9%; P < .001), larger median indexed LVEDD (normalized by BSA, 40 vs 33 mm/m2; P < .001), and lower median serum creatinine concentration (1.1 vs 1.3 mg/dL; P < .001). The proportion of patients achieving the composite end point at 2 years was 77% in both groups (adjusted hazard ratio, 1.14; 95% CI, 0.68-1.91; P = .62). Two-year adverse event rates were also similar between groups except for sepsis (6.1% vs 14.9%; P = .029) and cardiac arrhythmias (24.4% vs 35.3%; P = .005), which were higher in the larger patients. CONCLUSIONS: Outcomes after HM3 implantation were comparable between small and large patients. Smaller body size should not be used to deny HM3 implantation in patients who are otherwise suitable candidates for durable mechanical circulatory support.
引用
- Molina EJ, Cowger J, Lee S, et al. Outcomes in Smaller Body Size Adults After HeartMate 3 Left Ventricular Assist Device Implantation. Ann Thorac Surg. 2022. PMID: 35452663. doi:10.1016/j.athoracsur.2022.03.071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。